Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) — The "COVID-19 Vaccines: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global COVID-19 Vaccines Market to Reach $60.7 Billion by 2025
The COVID-19 Vaccines Market Report is your essential resource for data, insights, and strategic decision-making. This report provides an in-depth analysis of current market dynamics, dissecting intricate trends, and offering comprehensive competitor insights to shape your strategic choices.
Delve into the enormous market potential with a focus on the industry's projected growth. Evaluate the vaccine value's stability in major contributors like China and anticipate global vaccination rates in the upcoming years.
In 2020, annual COVID-19 vaccine doses were estimated at $255 million, set to soar to $60.7 billion by 2025. The value of annual doses in China is expected to level off at $23 billion by 2025, following a peak at $73 billion in 2021. Global vaccination rates are predicted to decrease to 47% by 2025, compared to the 73% estimated for 2022.
Africa is anticipated to reach a vaccinated population of only 12% by 2023, dwindling to 4% by 2025. In contrast, France is projected to achieve a vaccination rate of 92% by the end of 2022. Worldwide, the number of administered doses is expected to rise to 4,186 million by 2025. Don't miss out on these critical insights for informed decision-making.
Key Topics Covered:
COVID-19 VACCINE DEVELOPMENT – A GLOBAL MARKET OVERVIEW
Omicron Spreads Panic Worldwide; Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
South Africa: Omicron's Origin Location
Omicron: Impact on Travel Industry
Countries that have Already Detected Omicron Cases
Steps taken by the Countries to Prevent Transmission of Omicron Variant
Fears of Tourism Industry
Industry Response to the Travel Curbs
Short-term Impact of Omicron on Travel
Financial Impact
Scientists Seek to Gather More Information on Omicron
Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them?
At the Dawn of 2022, We Leave Behind Millions of Deaths Due to New Strains & Once Again Stare at an Impending Catastrophe
Split Scenarios Unfold: The Great Vaccine Divide Emerges
Amid this Prolonged Pandemic, Why Should Businesses Care About Progress on Vaccinations?
With IMF Making an Upward Revision of Global GDP for 2021, Companies Are Bullish About an Economic Comeback Despite a Continuing Pandemic
Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster Shots
Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Despite US Donation, Global Delivery of COVID-19 Vaccines Remains Far Short of Target
Anti-Vaccine Movement Poses Significant Threat
THE VARIOUS COVID-19 VIRUS VARIANTS
Emergence of Delta Variant Sparks New Wave of Infections
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
California Strain Emerges to be more Contagious and Deadly
Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
Less Effectiveness of AstraZeneca Vaccine Against South African Variant Leads to its Halt
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
US Government Unveils Covid-19 Vaccine Booster Shot Plan to Maximize Vaccine Protection Against Emerging Variants
AstraZeneca Vaccine Effective against New Emerging Variants
Sinovac Vaccines Effective against Mutated Variants of Coronavirus
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
COVID-19 Vaccine Approval Details
COVID-19 Vaccine Funding Details
Pfizer/BioNTech's COVID-19 Vaccine Receives World's First Authorization
UK Clinches the First Position in the World to Approve Pfizer's Vaccine
After UK, Pfizer's Vaccine Gains Approval from the US and EU
Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca's Vaccine – Third Globally to Obtain Approval
J&J's Single Shot Vaccination Resumes After Temporary Suspension
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
Russia Commences Mass Vaccination from Mid-December, 2020
Russia's Sputnik V Receives Approval for People Aged over 60
China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
China Issues License for Vaccine Production to Overseas Partners
Brazilian Authorities Approve Sinovac's CoronaVac
AstraZeneca's Covishield and Bharat Biotech's Covaxin Receive Emergency Use Approval in India
Sanofi-GSK to Offer Vaccine at a Discounted Rate
CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
Novavax Obtains First Authorization for its COVID-19 vaccine
mRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas
MARKET DYNAMICS
Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions & Ensure Public Safety
Developments Regarding Digital Certificates
COVID-19 Vaccine Passport: Insights & Progress
Regions/Countries Planning to Seek Vaccine Passport
mRNA Vaccines Offer More Protection Against Newer Variants
Vaccine Companies Stress on Booster Dose
Longer Interval between the Two Doses of Pfizer Vaccine to Boost Antibody Levels
Mix and Match is the New COVID-19 Vaccine Mantra
Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
Vaccine Alliances Ensure Supplies for All
Licensing and Partnership Deals Worldwide Propel Vaccine Production
VACCINES FOR KIDS
Kids: A Key to COVID-19 Controlling Efforts
US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11 Years, and 12 to 15 Years Age
Pfizer Approves Vaccine for Kids Aged 5-11 Years
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
FOCUS ON THE FRONTRUNNERS
Moderna, Inc. (USA)
Pfizer Inc./BioNTech (US/Germany)
AstraZeneca/University of Oxford (The UK)
Johnson & Johnson (USA)
CanSino Biologics, Inc. (China)
China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
Sinovac Biotech Ltd. (China)
Novavax, Inc. (USA)
Inovio Pharmaceuticals (USA)
Sanofi/GlaxoSmithKline (France/UK)
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism Hampers Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Protein-Subunit Vaccines
Non-Replicating Viral-Vector
Nucleic Acid Vaccines
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Virus-like Particle Vaccines
For more information about this report visit https://www.researchandmarkets.com/r/q8ijed
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Is Pfizer stock a buy or a sell after the FDA signed off on its updated Covid shot? Is PFE stock a buy or a sell right now?
Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy. The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not been shown effective for patients with the fatal, muscle-wasting disease known as ALS, or amyotrophic lateral sclerosis. One panel member abstained from voting.
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise
Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
Soleno said Tuesday its experimental pill helped control hunger signals in a genetic disorder. In response, SLNO stock skyrocketed.
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
Immunovant shares virtually doubled in value after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.
When Costco lists gold bars for sale online, "they're typically gone within a few hours and we limit two per member," its CFO told investors.
(Bloomberg) — Tesla Inc. Chief Executive Officer Elon Musk blasted the United Auto Workers Tuesday, saying the union’s demands would “drive GM, Ford and Chrysler bankrupt in the fast lane.” Most Read from BloombergChina Puts Evergrande’s Billionaire Founder Under Police ControlDimon Warns 7% Fed Rate Still Possible, Times of India SaysRepublican Moderates Turn to Rare Maneuver to Avoid Lengthy Government ShutdownIndians Have Five Days to Deposit $3 Billion in Soon-to-Be-Withdrawn BanknotesTrump
With WTI crude oil prices spiking 4% today and currently near $94 a barrel it's noteworthy that several Zacks Oils and Energy sector stocks are standing out with stellar dividend yields and the ability to benefit from the surging commodity price.
Warren Buffett isn't known for being a big real estate investor, but he has invested in real estate investment trusts (REITs) in the past and reaped significant rewards. For instance, Buffett's company Berkshire Hathaway Inc. (NYSE:BRK) used to own shares of STORE Capital Corp., a REIT specializing in single-tenant operational real estate (STORE). In September 2022, STORE Capital announced that it would be acquired by Singapore's sovereign wealth fund GIC and Oak Street in an all-cash transactio
Can investors realistically time the market to maximize returns, especially over the long term? According to a recent study from Charles Schwab, perfect market timing is practically impossible. The firm’s research showed that most investors are better off investing as soon as possible using a buy-and-hold strategy rather than trying to predict short-term peaks and […] The post Forget About ‘Timing the Market’: Schwab Research Reveals the Optimal Way to Invest appeared first on SmartReads by Smar
Tesla, BYD, NIO and Honda are part of the Zacks top Analyst Blog.
JPMorgan Chase made millions by keeping Jeffrey Epstein as a banking client. Now it faces a reckoning in federal court.
The markets have mostly been in a downtrend since midway through the summer, with a pensive mood driving the narrative. Concerns include higher oil prices, the prospect of interest rates remaining elevated for the time being, while worries about a recession are yet to abate. However, a new note from Bank of America’s head of US equity & quantitative strategy, Savita Subramanian, sets out the bullish case for the final quarter of 2023. “I see far more bullish indicators for mid and large-cap stoc
Just like that, Cathie Wood's ARK Innovation ETF plunged out of the top 10 — actually the top 15 ETFs this year.
The Idaho-based chipmaker's first-quarter revenue forecast exceeded Wall Street estimates, powered by demand for its memory chips from the rapidly growing artificial intelligence sector. Micron said it is working with Nvidia, the world's most valuable chip company, to qualify its newest high-bandwidth memory chips for use in Nvidia's computing chips. Demand for high-bandwidth memory chips, a market led by Nvidia supplier SK Hynix, for use in AI has also raised investor hopes that Micron will be able to weather a slow recovery in other end markets.
Stocks have suffered a rough September, with the S&P 500 dropping from 4,516 at the month's start to 4,275. Look out below?